clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02137850 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | Canada | Q16 |
Japan | Q17 | ||
United States of America | Q30 | ||
Spain | Q29 | ||
Italy | Q38 | ||
Austria | Q40 | ||
Greece | Q41 | ||
France | Q142 | ||
Germany | Q183 | ||
Romania | Q218 | ||
Bulgaria | Q219 | ||
Algeria | Q262 | ||
Australia | Q408 | ||
Argentina | Q414 | ||
Israel | Q801 | ||
Malaysia | Q833 | ||
Taiwan | Q865 | ||
Thailand | Q869 | ||
P582 | end time | 2021-11-13 | |
P4135 | maximum age | 6 | |
P1050 | medical condition | hemophilia A | Q2092064 |
P1132 | number of participants | 125 | |
P6153 | research site | Novo Nordisk | Q818846 |
P1813 | short name | pathfinder™6 | |
P580 | start time | 2014-06-26 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A |
Search more.